BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28038447)

  • 1. Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia.
    Zatula A; Dikic A; Mulder C; Sharma A; Vågbø CB; Sousa MML; Waage A; Slupphaug G
    Oncotarget; 2017 Mar; 8(12):19427-19442. PubMed ID: 28038447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles.
    Mosca L; Musto P; Todoerti K; Barbieri M; Agnelli L; Fabris S; Tuana G; Lionetti M; Bonaparte E; Sirchia SM; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omedè P; Boccadoro M; Palumbo A; Neri A
    Am J Hematol; 2013 Jan; 88(1):16-23. PubMed ID: 23044976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of p16(INK4A) expression in multiple myeloma and plasma cell leukemia.
    Urashima M; Teoh G; Ogata A; Chauhan D; Treon SP; Sugimoto Y; Kaihara C; Matsuzaki M; Hoshi Y; DeCaprio JA; Anderson KC
    Clin Cancer Res; 1997 Nov; 3(11):2173-9. PubMed ID: 9815612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
    Egan JB; Shi CX; Tembe W; Christoforides A; Kurdoglu A; Sinari S; Middha S; Asmann Y; Schmidt J; Braggio E; Keats JJ; Fonseca R; Bergsagel PL; Craig DW; Carpten JD; Stewart AK
    Blood; 2012 Aug; 120(5):1060-6. PubMed ID: 22529291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.
    Song S; Zhang J; Su Q; Zhang W; Jiang Y; Fan G; Qian C; Li B; Zhuang W
    Br J Cancer; 2021 May; 124(11):1843-1853. PubMed ID: 33785876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.
    Jimenez-Zepeda VH; Dominguez-Martinez VJ
    Int J Hematol; 2009 Apr; 89(3):259-268. PubMed ID: 19326058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current State of Knowledge About Evolution of Multiple Myeloma to Plasma Cell Leukemia.
    Jurczyszyn A; Olszewska-Szopa M; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):188-193. PubMed ID: 36593169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic aberrations and survival in plasma cell leukemia.
    Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
    Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
    Cha CH; Park CJ; Huh JR; Chi HS; Suh CW; Kang YK
    Acta Haematol; 2007; 118(3):178-82. PubMed ID: 17934254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
    Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
    Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma cell leukemia: a rare condition.
    Jiménez-Zepeda VH; Domínguez VJ
    Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
    Jurczyszyn A; Zawirska D; Skotnicki AB
    Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
    Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
    Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia.
    Chang H; Qi X; Yeung J; Reece D; Xu W; Patterson B
    Leuk Res; 2009 Feb; 33(2):259-62. PubMed ID: 18676019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia.
    Shimazaki C; Gotoh H; Ashihara E; Oku N; Inaba T; Murakami S; Itoh K; Ura Y; Nakagawa M; Fujita N
    Am J Hematol; 1992 Mar; 39(3):159-62. PubMed ID: 1546712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma cell leukemia.
    Albarracin F; Fonseca R
    Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cell leukemia: from biology to treatment.
    Jelinek T; Kryukov F; Rihova L; Hajek R
    Eur J Haematol; 2015 Jul; 95(1):16-26. PubMed ID: 25778450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.
    Lionetti M; Barbieri M; Todoerti K; Agnelli L; Marzorati S; Fabris S; Ciceri G; Galletti S; Milesi G; Manzoni M; Mazzoni M; Greco A; Tonon G; Musto P; Baldini L; Neri A
    Oncotarget; 2015 Sep; 6(27):24205-17. PubMed ID: 26090869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.